Drugs / OVX836
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03594890 | Jun 2018 → Aug 2019 | influenza | Osivax | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05569239 | Sep 2025 → May 2026 overdue | influenza | Osivax | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06582277 | Oct 2024 → Jun 2025 | influenza | Osivax | Completed | No outcome recorded |
| Phase 2 | NCT05734040 | May → Aug 2023 | influenza | Osivax | Completed | No outcome recorded |
| Phase 2 | NCT05284799 | May → Jul 2022 | influenza | Osivax | Completed | No outcome recorded |
| Phase 2 | NCT05060887 | Nov 2021 → Feb 2022 | influenza | Osivax | Completed | No outcome recorded |
| Phase 2 | NCT04192500 | Dec 2019 → Sep 2020 | influenza | Osivax | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVX836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04192500 ↗ |
| Action | Deplete | “an NP cell-mediated immune (CMI) response destroying infected cells” PMID 40573889 ↗ May 2025 |
| Modality | Vaccine | “The OVX836 recombinant vaccine is based on the well conserved nucleoprotein of the Influenza virus.” NCT03594890 ↗ |
| Route | Intramuscular | “administered either by the intramuscular route (Study Part A) or by the intranasal route (Study Part B)” NCT03594890 ↗ |
| Route | Intranasal | “administered either by the intramuscular route (Study Part A) or by the intranasal route (Study Part B)” NCT03594890 ↗ |